Literature DB >> 11476462

Double-blind multicenter study on the efficacy and tolerability of cetirizine compared with oxatomide in chronic idiopathic urticaria in preschool children.

M La Rosa1, S Leonardi, G Marchese, A Corrias, G Barberio, N Oggiano, I Grimaldi.   

Abstract

BACKGROUND: There are no studies on the use of cetirizine in children under the age of 6.
OBJECTIVE: We compared the efficacy and tolerability of cetirizine in patients with idiopathic chronic urticaria to the more widely used antihistamine, oxatomide.
METHODS: This double-blind study was performed on 62 patients (38 male and 24 female) with idiopathic chronic urticaria, recruited from four different medical centers of the national territory (Ancona, Cagliari, Catania, and Messina). The children's ages ranged from 2 to 6 years (mean 3.85). The patients were randomly assigned to two treatment groups: one group treated 31 children with cetirizine at a dosage of 5 mg q.d., and a second group treated 31 children for the same amount of time with oxatomide, at a dosage of 25 mg q.d. Sixty-two children began the treatment, but five did not finish the study (three in the cetirizine and two in the oxatomide group). Thus, the clinical study and the statistical evaluation were conducted on 57 children (28 cetirizine and 29 oxatomide). The Student's t test was used to compare severity of the illness and changes in the hematochemical tests.
RESULTS: Overall, the effectiveness of the two medications in treating erythema, papules, edema, and itching showed comparable therapeutic activity (P < 0.001). Neither medication produced significant side effects.
CONCLUSIONS: The results of the present study suggest that cetirizine may represent an effective and safe pharmacologic therapy for chronic urticaria in preschool children. There was no evidence for changes in hematochemical and urinary values, demonstrating the safety and the tolerability of the two antihistamines, even when given to young children.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476462     DOI: 10.1016/S1081-1206(10)62322-8

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN: 1081-1206            Impact factor:   6.347


  5 in total

Review 1.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Cetirizine: a review of its use in allergic disorders.

Authors:  Monique P Curran; Lesley J Scott; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  The KAAACI/KDA Evidence-Based Practice Guidelines for Chronic Spontaneous Urticaria in Korean Adults and Children: Part 1. Definition, Methodology and First-line Management.

Authors:  Woo Jung Song; Mira Choi; Dong Hun Lee; Jae Woo Kwon; Gun Woo Kim; Myung Hwa Kim; Mi Ae Kim; Min Hye Kim; Byung Keun Kim; Sujeong Kim; Joung Soo Kim; Jung Eun Kim; Ju Young Kim; Joo Hee Kim; Hyun Jung Kim; Hye One Kim; Hyo Bin Kim; Joo Young Roh; Kyung Hee Park; Kui Young Park; Han Ki Park; Hyunsun Park; Jung Min Bae; Ji Yeon Byun; Dae Jin Song; Young Min Ahn; Seung Eun Lee; Young Bok Lee; Joong Sun Lee; Ji Hyun Lee; Kyung Hwan Lim; Young Min Ye; Yoon Seok Chang; You Hoon Jeon; Jiehyun Jeon; Mihn Sook Jue; Sun Hee Choi; Jeong Hee Choi; Gyu Young Hur; Young Min Park; Dae Hyun Lim; Sang Woong Youn
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

Review 4.  Cetirizine use in childhood: an update of a friendly 30-year drug.

Authors:  Giuseppe Fabio Parisi; Salvatore Leonardi; Giorgio Ciprandi; Angelo Corsico; Amelia Licari; Michele Miraglia Del Giudice; Diego Peroni; Carmelo Salpietro; Gian Luigi Marseglia
Journal:  Clin Mol Allergy       Date:  2020-02-26

Review 5.  Management of Pediatric Chronic Spontaneous Urticaria: A Review of Current Evidence and Guidelines.

Authors:  Jasmine Chang; Leila Cattelan; Moshe Ben-Shoshan; Michelle Le; Elena Netchiporouk
Journal:  J Asthma Allergy       Date:  2021-03-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.